Briacell Therapeutics CorpNASDAQ:BCTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)View on Canadian Exchange
- LAST PRICE0.5950
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5688/ 51
- Ask / Lots0.6006/ 4
- Open / Previous Close--- / 0.5950
- Day Range---
- 52 Week Range
- Volume300
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCTX |
|---|---|---|
| 09:32 ET | 4363 | 0.6 |
| 09:35 ET | 100 | 0.605001 |
| 09:37 ET | 5300 | 0.608001 |
| 09:39 ET | 200 | 0.608001 |
| 09:44 ET | 200 | 0.606 |
| 09:46 ET | 1100 | 0.606 |
| 09:48 ET | 750 | 0.6 |
| 09:50 ET | 100 | 0.6 |
| 09:51 ET | 250 | 0.604999 |
| 10:00 ET | 15428 | 0.5965 |
| 10:04 ET | 852 | 0.6 |
| 10:08 ET | 1000 | 0.6 |
| 10:11 ET | 200 | 0.6 |
| 10:20 ET | 4735 | 0.5951 |
| 10:22 ET | 100 | 0.6 |
| 10:24 ET | 2974 | 0.6 |
| 10:26 ET | 5173 | 0.6 |
| 10:27 ET | 1600 | 0.5964 |
| 10:29 ET | 3000 | 0.5993 |
| 10:36 ET | 243 | 0.595 |
| 10:45 ET | 100 | 0.598 |
| 10:47 ET | 500 | 0.602816 |
| 10:49 ET | 800 | 0.6014 |
| 10:58 ET | 100 | 0.6 |
| 11:00 ET | 500 | 0.599 |
| 11:07 ET | 1100 | 0.599 |
| 11:09 ET | 5100 | 0.602 |
| 11:14 ET | 200 | 0.599 |
| 11:23 ET | 5100 | 0.6008 |
| 11:25 ET | 4450 | 0.599 |
| 11:27 ET | 7586 | 0.5902 |
| 11:30 ET | 1200 | 0.595 |
| 11:39 ET | 10105 | 0.6 |
| 11:43 ET | 1370 | 0.6 |
| 11:45 ET | 5110 | 0.5904 |
| 11:48 ET | 9400 | 0.5976 |
| 11:50 ET | 207 | 0.599999 |
| 11:52 ET | 10300 | 0.5974 |
| 11:54 ET | 2300 | 0.5975 |
| 11:57 ET | 2643 | 0.5975 |
| 12:15 ET | 200 | 0.5951 |
| 12:32 ET | 1000 | 0.5902 |
| 12:33 ET | 100 | 0.591 |
| 12:42 ET | 180 | 0.597 |
| 12:46 ET | 2842 | 0.5903 |
| 12:50 ET | 162 | 0.5903 |
| 12:51 ET | 3119 | 0.59 |
| 12:53 ET | 1979 | 0.59 |
| 12:57 ET | 900 | 0.5901 |
| 01:06 ET | 3405 | 0.5901 |
| 01:09 ET | 1311 | 0.5979 |
| 01:15 ET | 1662 | 0.5901 |
| 01:18 ET | 384 | 0.5901 |
| 01:24 ET | 23728 | 0.583 |
| 01:26 ET | 1970 | 0.5832 |
| 01:27 ET | 400 | 0.5832 |
| 01:31 ET | 400 | 0.5832 |
| 01:33 ET | 2300 | 0.5839 |
| 01:36 ET | 1000 | 0.5891 |
| 01:38 ET | 100 | 0.5923 |
| 01:40 ET | 3000 | 0.58775 |
| 01:42 ET | 2261 | 0.5878 |
| 01:49 ET | 8338 | 0.5838 |
| 02:07 ET | 400 | 0.5826 |
| 02:09 ET | 100 | 0.581 |
| 02:12 ET | 900 | 0.5817 |
| 02:16 ET | 5100 | 0.581001 |
| 02:32 ET | 900 | 0.5818 |
| 02:34 ET | 1000 | 0.58425 |
| 02:39 ET | 100 | 0.5821 |
| 02:41 ET | 342 | 0.5821 |
| 02:45 ET | 400 | 0.58194 |
| 02:50 ET | 100 | 0.582 |
| 02:59 ET | 5119 | 0.5817 |
| 03:01 ET | 5500 | 0.582 |
| 03:03 ET | 100 | 0.582 |
| 03:06 ET | 842 | 0.5891 |
| 03:15 ET | 1000 | 0.582 |
| 03:17 ET | 11540 | 0.582 |
| 03:28 ET | 3165 | 0.5924 |
| 03:30 ET | 1000 | 0.5854 |
| 03:35 ET | 100 | 0.582 |
| 03:39 ET | 700 | 0.5884 |
| 03:42 ET | 2000 | 0.5892 |
| 03:46 ET | 906 | 0.59 |
| 03:48 ET | 10000 | 0.59 |
| 03:51 ET | 7815 | 0.595 |
| 03:55 ET | 1000 | 0.585 |
| 04:00 ET | 2279 | 0.595 |
Nov 8, 2024
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference, from 7:50AM ET on Friday Nov 08, 2024 by Dow Jones
7:50AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 4, 2024
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium(R), December 10 -- 13, from 7:50AM ET on Monday Nov 04, 2024 by Dow Jones
7:50AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 22, 2024
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data, from 7:50AM ET on Tuesday Oct 22, 2024 by Dow Jones
7:50AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Briacell Therapeutics Corp | 29.4M | 0.0x | --- |
Company Information
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Contact Information
- Headquarters
- Suite 300 - Bellevue Centre 235 -15th StreetWEST VANCOUVER, BC, Canada V7T 2X1
- Phone
- 604-921-1810
- Fax
- 604-921-1898
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.43 |
Book Value | $-0.18 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
